Michel Detheux
2021
In 2021, Michel Detheux earned a total compensation of $5.6M as Ph.D. Chief Executive Officer at iTeos Therapeutics, a 67% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $301,426 |
|---|---|
| Option Awards | $4,664,131 |
| Salary | $525,417 |
| Other | $109,653 |
| Total | $5,600,627 |
Detheux received $4.7M in option awards, accounting for 83% of the total pay in 2021.
Detheux also received $301.4K in non-equity incentive plan, $525.4K in salary and $109.7K in other compensation.
Rankings
In 2021, Michel Detheux's compensation ranked 2,281st out of 12,415 executives tracked by ExecPay. In other words, Detheux earned more than 81.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,281 out of 12,415 | 82nd |
Division Manufacturing | 890 out of 5,505 | 84th |
Major group Chemicals And Allied Products | 341 out of 2,375 | 86th |
Industry group Drugs | 295 out of 2,096 | 86th |
Industry Biological Products, Except Diagnostic Substances | 92 out of 449 | 80th |
Source: SEC filing on April 25, 2022.
Detheux's colleagues
We found two more compensation records of executives who worked with Michel Detheux at iTeos Therapeutics in 2021.
News
iTeos Therapeutics CEO Michel Detheux's 2023 pay falls 45% to $5.8M
April 25, 2024
iTeos Therapeutics CEO Michel Detheux's 2022 pay jumps 88% to $11M
April 27, 2023
iTeos Therapeutics CEO Michel Detheux's 2021 pay falls 67% to $5.6M
April 25, 2022
iTeos Therapeutics CEO Michel Detheux's 2020 pay jumps 964% to $17M
May 5, 2021